{"id":1163,"date":"2016-10-01T12:06:00","date_gmt":"2016-10-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/ueberlebensvorteil-herzinsuffizienter-patienten-die-mit-sacubitril-valsartan-behandelt-werden"},"modified":"2016-10-01T12:06:00","modified_gmt":"2016-10-01T10:06:00","slug":"ueberlebensvorteil-herzinsuffizienter-patienten-die-mit-sacubitril-valsartan-behandelt-werden","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/ueberlebensvorteil-herzinsuffizienter-patienten-die-mit-sacubitril-valsartan-behandelt-werden","title":{"rendered":"\u00dcberlebensvorteil herzinsuffizienter Patienten, die mit Sacubitril\/Valsartan behandelt werden"},"content":{"rendered":"<p>Frage von Dr. P.G. aus M.: >> In einem Leserbrief stellen B. Claggett et al. im N. Engl. J. Med. eine Berechnung des Langzeitnutzens von Entresto\u00ae vor, die sie aufgrund der Daten der PARADIGM-Studie angestellt haben (7). Sie kommen zu dem Ergebnis, und dies wird von Vertretern der Firma den \u00c4rzten als Fakt so mitgeteilt, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frage von Dr. P.G. aus M.: >> In einem Leserbrief stellen B. Claggett et al. im N. Engl. J. Med. eine Berechnung des Langzeitnutzens von Entresto\u00ae vor, die sie aufgrund der Daten der PARADIGM-Studie angestellt haben (7). Sie kommen zu dem Ergebnis, und dies wird von Vertretern der Firma den \u00c4rzten als Fakt so mitgeteilt, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[316,309,312,314,313,315,1563,1564,317,320,311,307,319,310,180,1567,1566,1562,1560,306,366],"class_list":["post-1163","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-angiotensin-rezeptor-neprilysin-inhibitor","tag-arni","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-herzinsuffizienz","tag-lcz696","tag-paradigm-hf-studie","tag-sacubitril","tag-sacubitril-valsartan","tag-sartane","tag-valsartan"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1163"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1163\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}